Winton Group LTD Neurocrine Biosciences Inc Transaction History

Winton Group LTD

$1.31 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$130.86 - $143.19 $1.4 Million - $1.53 Million	10,689 New	10,689 $1.47 Million
Q4 2023 Feb 12, 2024	SELL	$106.07 - $132.76 $12,410 - $15,532	-117 Reduced 2.74%	4,155 $547,000
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $163,406 - $203,519	1,738 Added 68.59%	4,272 $480,000
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $3.56 Million - $4.16 Million	-39,708 Reduced 94.0%	2,534 $238,000
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $1.18 Million - $1.54 Million	12,542 Added 42.23%	42,242 $4.28 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $1.75 Million - $2.09 Million	-16,429 Reduced 35.62%	29,700 $3.55 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $262,193 - $307,150	2,849 Added 6.58%	46,129 $4.9 Million
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $513,325 - $677,774	6,773 Added 18.55%	43,280 $4.22 Million
Q1 2022 May 11, 2022	SELL	$72.45 - $94.81 $286,467 - $374,878	-3,954 Reduced 9.77%	36,507 $3.42 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $1.59 Million - $2.12 Million	19,957 Added 97.33%	40,461 $3.45 Million
Q3 2021 Oct 28, 2021	SELL	$86.18 - $99.03 $110,568 - $127,055	-1,283 Reduced 5.89%	20,504 $1.97 Million
Q2 2021 Aug 10, 2021	SELL	$89.43 - $102.27 $85,405 - $97,667	-955 Reduced 4.2%	21,787 $2.12 Million
Q1 2021 Jul 21, 2021	BUY	$87.57 - $119.4 $102,019 - $139,101	1,165 Added 5.4%	22,742 $2.21 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $3.66 Million - $4.56 Million	-42,075 Reduced 66.1%	21,577 $2.07 Million
Q3 2020 Oct 30, 2020	BUY	$96.16 - $135.15 $783,607 - $1.1 Million	8,149 Added 14.68%	63,652 $6.12 Million
Q2 2020 Aug 05, 2020	BUY	$85.09 - $130.36 $1.22 Million - $1.87 Million	14,363 Added 34.91%	55,503 $6.77 Million
Q1 2020 May 11, 2020	BUY	$75.11 - $113.76 $563,024 - $852,744	7,496 Added 22.28%	41,140 $3.56 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $1.78 Million - $2.43 Million	20,505 Added 156.06%	33,644 $3.62 Million
Q3 2019 Nov 08, 2019	BUY	$83.82 - $101.5 $1.1 Million - $1.33 Million	13,139 New	13,139 $1.18 Million
Q2 2019 Jul 08, 2019	SELL	$72.24 - $91.27 $322,985 - $408,068	-4,471 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$69.31 - $91.53 $94,746 - $125,121	-1,367 Reduced 23.42%	4,471 $394,000
Q4 2018 Feb 05, 2019	SELL	$68.32 - $124.36 $15,440 - $28,105	-226 Reduced 3.73%	5,838 $417,000
Q3 2018 Nov 02, 2018	SELL	$98.88 - $125.85 $5,339 - $6,795	-54 Reduced 0.88%	6,064 $0
Q2 2018 Aug 20, 2018	SELL	$75.3 - $105.99 $252,857 - $355,914	-3,358 Reduced 35.44%	6,118 $0
Q1 2018 May 21, 2018	BUY	$75.88 - $92.43 $719,038 - $875,866	9,476 New	9,476 $0

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$1.77 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.25 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$644 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$322 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$233 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.

Account